Physician profile
Charles Brian Waitkus
NPI 1083694129
$1,183.57
in general payments reported to CMS, 2019-2025
15 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $237 · 2020: $73.12 · 2021: $127 · 2022: $124 · 2023: $132 · 2024: $293 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $244.12 | 2021-2024 | Simbrinza, Total30 |
| Abbvie INC. | $166.78 | 2024-2025 | |
| Maculogix, INC. | $138.16 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $120.27 | 2022-2025 | Infuse, Biotrue One Day |
| Mallinckrodt Hospital Products INC. | $98.24 | 2025 | Acthar |
| Dompe US, INC. | $75.03 | 2024 | Oxervate |
| Penumbra, INC. | $73.44 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $69.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $57.32 | 2019-2023 | Cequa |
| Coopervision INC. | $31.44 | 2019 | |
| Oyster Point Pharma, INC. | $28.09 | 2022 | |
| Allergan, INC. | $25.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.60 | 2019 | |
| Kala Pharmaceuticals, INC. | $16.05 | 2022 | |
| Shire North American Group INC | $15.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Waitkus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.